Statement: The patient group with the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients.
Primary_evidence: Outcome Measurement:    Event-free Survival   Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF.   Time frame: 11 years Results 1:    Arm/Group Title: TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer   Arm/Group Description: See Detailed Description.   tamoxifen citrate: Given orally   busulfan: Given orally   thiotepa: Given IV   melphalan: Given IV   aldesleukin: Given SC   sargramostim: Given SC   peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion   radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF   Overall Number of Participants Analyzed: 50   Measure Type: Count of Participants   Unit of Measure: Participants  Stage IIIB Disease: 18 participants   11  61.1%   Stage IV Disease: 32 participants 9  28.1%